• MiRNA-320 as a novel therapeutic target in Prostate cancer
  • Rouhallah Moradpour,1,*
    1. Center for Cell Pathology Research, Department of Life Sciences, Khazar University, Baku, Azerbaijan.


  • Introduction: Prostate cancer remains the most prevalent noncutaneous cancer, leading to almost 30 000 deaths every year in men. Although risk reduction of prostate cancer has been somewhat successful, effective prevention is still lacking. Immunotherapeutic approaches, although moderately complicated, remain promising in an effort to control the progression and development of the disease. Taken together, the parameters of epidemiological studies and immunotherapeutic regimens might eventually be the most effective and preventive approach for prostate cancer. MiRNAs are endogenous 21–22-nucleotide (nt) noncoding small RNAs. This review highlights some of the events associated with the development and prevention of prostate cancer.
  • Methods: In this study, The PC3 and DU145 cell lines were maintained in RPMI media 1640 supplemented with 10% FBS and cultured under standard conditions of 95% humidity and 5% CO2 at 37 °C. Transfection of miR-320 mimic and negative control (NC) was established using Electroporation technique. Electroporation is a physical transfection method that uses an electrical pulse to create temporary pores in cell membranes through which substances like nucleic acids can pass into the cells. MTT assay was performed to investigate the cytotoxic effect of miR-320 mimic PC3 and DU145 cell lines. Cytotoxic performed using the MTT method, the optimum of which was determined to be 40.
  • Results: These findings indicate that transfected miR-320 mimic could suppress PC3 and DU145 proliferation.
  • Conclusion: As expected, these results confirm the tumor-suppressive effect of miR-320 in the PC3 and DU145 prostate cancer cell lines by reducing proliferation.
  • Keywords: prostate cancer, microRNA-320, proliferation, electroporation and MTT assay.